Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours

被引：6

作者：

Bazhenova, L. ^{[1
]}

Liu, S. V. ^{[2
]}

Lin, J. J. ^{[3
]}

Lu, S. ^{[4
]}

Drilon, A. ^{[5
]}

Chawla, S. P. ^{[6
,7
]}

Fakih, M. ^{[8
]}

Krzakowski, M. ^{[9
]}

Paz-Ares, L. ^{[10
]}

Blakely, C. ^{[11
]}

Buchschacher, G. L., Jr. ^{[12
]}

Cassier, P. ^{[13
]}

Fan, Y. ^{[14
]}

Folprecht, G. ^{[15
]}

McCallum, S. ^{[16
]}

Pitcher, B. ^{[17
]}

Chen, D. ^{[18
]}

Freund, R. ^{[19
]}

Springfeld, C. ^{[20
]}

机构：

[1] Univ Calif San Diego, Moores Canc Ctr, Dept Med, San Diego, CA 92103 USA

[2] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA

[3] Massachusetts Gen Hosp, Dept Hematol Oncol, Canc Ctr, Boston, MA 02114 USA

[4] Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

[5] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Sarcoma Oncol Ctr, Santa Monica, CA USA

[8] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

[9] Maria Sklodowska Curie Inst, Dept Lung & Chest Canc, Ctr Oncol, Warsaw, Poland

[10] Univ Complutense Ciberonc, Hosp Univ 12 Octubre, Dept Med Oncol, CNIO H12o Lung Canc Clin Res Unit, Madrid, Spain

[11] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[12] Los Angeles Med Ctr, Dept Hematol Oncol, Kaiser Permanente Southern Calif, Los Angeles, CA USA

[13] Ctr Leon Berard, Dept Med, Lyon, France

[14] Zhejiang Canc Hosp, Med Dept Thorac Oncol, Hangzhou, Peoples R China

[15] Univ Hosp Carl Gustav Carus, Univ Canc Ctr, Med Dept Unit Med Oncol, Dresden, Germany

[16] Genentech Inc, Medicat Safety & Risk Management, San Francisco, CA 94080 USA

[17] F Hoffmann La Roche Ltd, Stat Sci, Mississauga, ON, Canada

[18] Genentech Inc, Clin Sci, San Francisco, CA 94080 USA

[19] F Hoffmann La Roche Ltd, Med Oncol, Basel, Switzerland

[20] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

533P

引用

页码：S598 / S599

页数：2

共 50 条

[31] Larotrectinib in NTRK Fusion-Positive Locally Advanced or Metastatic Soft Tissue Sarcomas in Children: A Case Series
Asarcikli, F.
Kebudi, R.
Sozmen, B. Oflaz
Erbey, F.
Buyukkapu, S. Bay
PEDIATRIC BLOOD & CANCER, 2021, 68 : S262 - S262
[32] Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Rolfo, C.
Dziadziuszko, R.
Doebele, R. C.
Demetri, G.
Simmons, B.
Aziez, A.
Huang, X.
Osborne, S.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2019, 30
[33] ESMO 2018-Pooled Analysis confirms pan-Tumor Efficacy of Entrectinib in NTRK Fusion-positive Solid Tumors
不详
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (12) : 796 - 796
[34] Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis
Krebs, M. G.
De Braud, F.
Siena, S.
Drilon, A.
Doebele, R. C.
Patel, M. R.
Cho, B. C.
Liu, S. V.
Ahn, M-J.
Chiu, C-H.
Farago, A. F.
Lin, C-C.
Karapetis, C. S.
Li, Y-C.
Barlesi, F.
Simmons, B.
Pitcher, B.
Dziadziuszko, R.
ANNALS OF ONCOLOGY, 2020, 31 : S831 - S833
[35] Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusion-positive, Recurrent or Advanced Solid Tumors
Osman, Hind M.
Tuncbilek, Meral
CURRENT MEDICINAL CHEMISTRY, 2022, 29 (15) : 2602 - 2616
[36] Updated Efficacy and Safety of Entrectinib in Patients (PTS) with NTRK Fusion-Positive (NTRK plus ) Tumors: Integrated Analysis of STARTRK-2, STARTRK-1, and ALKA-372-001
Folprecht, Gunnar
Rolfo, Christian
Dziadziuszko, Rafal
Doebele, Robert
Demetri, George
Simmons, Brian
Huang, Xinhui
Pitcher, Bethany
Paz-Ares, Luis
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 216 - 217
[37] Safety of current treatment options for NTRK fusion-positive cancers
Yang, Adeline T.
Laetsch, Theodore Willis
EXPERT OPINION ON DRUG SAFETY, 2023, 22 (11) : 1073 - 1089
[38] Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp nonsmall cell lung cancer (NSCLC)
Lu, S.
Fan, Y.
Chiu, C-H.
Yu, Y.
Loong, H. H. F.
Lin, C-C.
Dong, X.
Li, J.
Zhao, J.
Zhang, Z.
Zhao, N.
Xu, T.
Hou, M.
Wang, D.
Hu, X.
ANNALS OF ONCOLOGY, 2022, 33 : S1536 - S1536
[39] COST-EFFECTIVENESS ANALYSIS OF LAROTRECTINIB AND ENTRECTINIB FOR ADULT PATIENTS WITH NTRK GENE FUSION-POSITIVE BREAST CANCER
Dheer, P.
Kamerikar, V
Fleming, M.
Seoane-Vazquez, E.
VALUE IN HEALTH, 2024, 27 (06) : S110 - S110
[40] COST-EFFECTIVENESS ANALYSIS OF ENTRECTINIB FOR TREATMENT NTRK FUSION-POSITIVE TUMORS IN CZECH REPUBLIC
Dolezel, J.
Pour, M.
Motylova, S.
Novak, J.
Skalicky, D.
VALUE IN HEALTH, 2022, 25 (12) : S101 - S101

← 1 2 3 4 5 →